KALA BIO Discloses Nearly 20% Share Dilution from Settlements with Baker Bros. and LifeSci

summarizeSummary

KALA BIO filed a proxy statement supplement disclosing the issuance of 4.6 million new shares, representing nearly 20% dilution, to settle claims with Baker Bros. and payment obligations with LifeSci Capital.

check_boxKey Events · Financing and Capital Events · KALA

• Significant Share Dilution

  The company issued 4.6 million new shares, increasing the total outstanding shares from 23,249,725 to 27,849,725, representing a nearly 20% dilution for existing shareholders.

• Settlement with Baker Bros.

  KALA BIO issued 900,000 shares of Common Stock to Baker Bros. Advisors LP to resolve claims related to prior financing arrangements. A voting agreement grants the company an irrevocable proxy for these shares for six months.

• Settlement with LifeSci Capital

  The company issued 2,200,000 shares of Common Stock to LifeSci Capital LLC to settle payment obligations for financial advisory services.

• Updated Outstanding Shares

  The total number of Common Stock shares outstanding as of December 30, 2025, was updated to 27,849,725, reflecting these issuances and other private placements.

auto_awesomeAnalysis · KALA · Life Sciences

KALA BIO has significantly increased its outstanding shares by approximately 20% through recent issuances to settle claims and payment obligations. While resolving these liabilities is a necessary step, the substantial dilution could pressure the stock price and reduce the value of existing shareholder equity. The voting agreement with Baker Bros. provides the company with temporary control over a portion of these newly issued shares, which could offer some stability in governance.